LQDA Overview

Liquidia Corporation is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products for cardiopulmonary diseases. The Company operates within the biotechnology sector, focusing on treatments for conditions such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enables precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is a PRINT‑engineered inhaled dry‑powder formulation of treprostinil designed to enhance deep lung delivery, improve therapeutic performance, and enable higher dose administration through a convenient inhaler.

Wall Street analysts forecast LQDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LQDA is47.50 USD with a low forecast of 31.00 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Liquidia Corp revenue for the last quarter amounts to 132.87M USD, increased 4158.49

Liquidia Corp. EPS for the last quarter amounts to 0.52 USD, decreased -215.56

Liquidia Corp (LQDA) has 216 emplpoyees as of June 19 2026.

Today LQDA has the market capitalization of 6.32B USD.